Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza vaccine (seasonal adjuvant) refers to a seasonal influenza vaccine formulation that incorporates an adjuvant to enhance the immune response, particularly in populations with reduced vaccine responsiveness such as the elderly. In the context of Vaxine Pty Ltd and the VaxCelerate Consortium, this specifically refers to a vaccine candidate utilizing the proprietary Advax adjuvant. Advax is a unique polysaccharide adjuvant derived from delta inulin that enhances both humoral (antibody) and cellular (T-cell) immunity without the high levels of inflammation associated with traditional adjuvants. The vaccine typically targets multiple strains of Influenza A (such as H1N1 and H3N2) and Influenza B, aiming to provide superior protection and potentially broader cross-reactivity against seasonal viral variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine (seasonal adjuvant).